BTK has not been well described in RCC, however interleukin-2-inducible T cell kinase (ITK) is also inhibited by ibrutinib (an off-target effect) and has been described to have immune-modulatory effects (see novel BTK inhibitor combinations below). This evidence concerns the gene BTK and renal cell carcinoma.